Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo pill could help diabetics on insulin

NCT ID NCT02220920

Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding canagliflozin, a diabetes pill, to insulin therapy helps people with type 2 diabetes control their blood sugar better. 146 adults took either canagliflozin or a placebo for 16 weeks while continuing their insulin. Researchers measured changes in blood sugar levels, weight, and safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Canagliflozin (a drug that helps lower blood sugar by making the kidneys remove extra sugar through urine)
What this could lead to
If successful, this could show that adding canagliflozin to insulin helps people with type 2 diabetes better control their blood sugar and possibly lose weight.
What could go wrong
This is a small, short-term (16-week) study, so results may not apply to long-term use. There is a risk of hypoglycemia (low blood sugar) when combining with insulin.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

146 people

The number who actually took part.

Start date

Aug 2014

Finished

Jul 2015

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who has been receiving a stable dose and regimen of insulin over 12 weeks before administration of investigational dug * Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug * Patients with HbA1c of ≥7.5% and \<10.5% * Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug Exclusion Criteria: * Patients with type 1 diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes mellitus (Cushing's syndrome, acromegaly, etc.) * Patients with severe diabetic complications (proliferative diabetic retinopathy, stage 4 nephropathy, or serious diabetic neuropathy) * Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria * Patients with systolic blood pressure of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg * Patients with serious renal or hepatic disease * Patients with eGFR of \<45 mL/min/1.73 m2 * Patients who are the excessive alcohol addicts * Patients who are pregnant, lactating and probably pregnant patients and patients who can not agree to contraception

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes mellitus

Contacts and locations

Locations

  • Reserch site

    Chugoku, Japan

  • Reserch site

    Chūbu, Japan

  • Reserch site

    Hokkaido, Japan

  • Reserch site

    Kanto, Japan

  • Reserch site

    Kinki, Japan

  • Reserch site

    Kyushu, Japan

  • Reserch site

    Tōhoku, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.